Evotec Starts Clinical Development of Chikungunya Antibody together with NIAID and Leading Academic Research Organisation
FIRST DOSE OF EVT894, A MONOCLONAL ANTIBODY AGAINST CHIKUNGUNYA VIRUS ADMINISTERED TO A HEALTHY PARTICIPANT IN A PHASE I STUDY...